ABSTRACT
This prospective, double-blind study used invasive monitoring and echo-Doppler techniques to compare the hemodynamic effects of nebivolol, a new beta 1-selective beta-blocking agent with those of atenolol in patients recovering from coronary artery bypass grafting surgery. Five milligrams nebivolol and 50 mg atenolol equally decreased heart rate (HR) and blood pressure (BP) but, nebivolol, in contrast to atenolol, caused no decrease in stroke index (SI), cardiac index (CI), and right ventricular ejection fraction (RVEF). These differences appeared to be related in part to different peripheral effects of the two agents because nebivolol administration was associated with a reduction in systemic vascular resistance (SVR). After < or = 10 days of treatment, acceleration of aortic flow velocity increased and isovolumic relaxation time decreased with nebivolol but not with atenolol treatment. Both drugs were equally well tolerated. Therefore, nebivolol shares most of its effects with classical beta 1-blockers but is devoid of the potentially harmful effects on cardiac output (CO) and peripheral resistance.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Atrial Function, Left/drug effects , Benzopyrans/therapeutic use , Coronary Artery Bypass/adverse effects , Ethanolamines/therapeutic use , Postoperative Complications/prevention & control , Adrenergic beta-1 Receptor Antagonists , Adrenergic beta-Antagonists/adverse effects , Aged , Atenolol/adverse effects , Atenolol/therapeutic use , Benzopyrans/adverse effects , Blood Volume/drug effects , Blood Volume/physiology , Double-Blind Method , Echocardiography, Doppler , Ethanolamines/adverse effects , Female , Humans , Male , Middle Aged , Nebivolol , Postoperative Complications/diagnostic imaging , Prospective Studies , Stroke Volume/drug effects , Tachycardia, Supraventricular/prevention & control , Transducers, Pressure , Vascular Resistance/drug effectsABSTRACT
One of the most important problems during cardiac surgery is the prevention and treatment of hypertension, occurring in 40-60% of the patients following coronary artery bypass surgery (CABS). Hypertension should be avoided to prevent myocardial damage, neurologic complications, increased blood loss, and premature graft closure due to intimal damage. During and following cardiac surgery hypertension is routinely treated with vasodilating agents, which generally induce reflex tachycardia and increased intrapulmonary shunting. The results obtained with ketanserin, a specific S2-serotonergic receptor blocker with alpha 1-adrenergic receptor blocking properties, in the prevention and treatment of hypertension in patients undergoing cardiac surgery, are presented. Ketanserin effectively lowers blood pressure by decreasing systemic vascular resistance but does not completely prevent perioperative and postoperative hypertension when administered as a continuous infusion from the start of anesthesia. In contrast to sodium nitroprusside, ketanserin does not induce reflex tachycardia in the treatment of postoperative systemic hypertension following CABS. The compound improves diuresis and perfusion of the skin perioperatively. Ketanserin is devoid of rebound phenomena after its administration is stopped. It is postulated that the antihypertensive effect of ketanserin can be explained by its property of simultaneously blocking alpha 1-adrenergic and S2-serotonergic receptors.
Subject(s)
Coronary Artery Bypass , Hypertension/drug therapy , Ketanserin/therapeutic use , Blood Pressure , Cardiac Output , Fentanyl/therapeutic use , Heart Rate , Humans , Hypertension/prevention & control , Intensive Care Units , Intraoperative Complications/drug therapy , Nitroglycerin/therapeutic use , Postoperative Complications/drug therapy , Pulmonary Artery/physiopathology , Skin Temperature , Vascular ResistanceABSTRACT
One thousand eleven patients with essential hypertension (H) were evaluated upon compliance with the following inclusion criteria: (a) mild to moderate uncomplicated H, with supine diastolic blood pressure (Su DBP) greater than 90 mm Hg at the end of the placebo period, with or without antihypertensive treatment; (b) greater than 20 years old. The dosage of ketanserin (K) was 20 mg b.i.d. up to the fourth week. Afterwards, if the patients normalized, we continued with the same schedule. If this did not occur, the dosage was increased (40 mg b.i.d.) up to the eighth week. Four hundred fifty-one men and 560 women were included, with a mean age of 56.6 years, mean body weight 74.8 kg, and mean height 166.30 cm. At the end of the eighth week, the percentage of normalization was 75.5% of the patients, and the percentage of partial responders was 5.6%. The decrease of the blood pressure (diastolic and systolic) was significant at the second week (paired t test, two-tailed probability, p less than or equal to 0.001). There were 62 dropouts: 10 due to inefficacy, 14 due to adverse reaction, and 38 due to other reasons. Laboratory examinations were performed before and after treatment and did not show statistical differences. Also, a 12-lead ECG was performed before and after treatment with K. The QTc was analyzed in a sample of 140 patients and did not show statistically significant changes. The incidence of side effects was minimal (24% of the patients, n = 224), mild, and transient; only 1% of the patients dropped out due to adverse reactions. In our experience, ketanserin was an effective and safe drug, to be used primarily for the treatment of mild to moderate H.
Subject(s)
Hypertension/drug therapy , Ketanserin/therapeutic use , Adult , Aged , Aged, 80 and over , Blood Pressure/drug effects , Central Nervous System/drug effects , Clinical Trials as Topic , Female , Humans , Hypertension/physiopathology , Ketanserin/administration & dosage , Ketanserin/adverse effects , Male , Middle AgedABSTRACT
In patients developing hypertension following coronary artery bypass surgery (CABG) the possible role of 5-hydroxytryptamine (5-HT; serotonin) was investigated by injecting ketanserin, a specific 5-HT2-receptor antagonist. Ketanserin was administered intravenously when intraarterial systolic blood pressure (SAP) exceeded 150 mm Hg either as a 10-mg bolus (group 1, N = 15), or as a 10-mg bolus followed by infusion of 4 mg/h for either 2.5 h (group 2, N = 15) or for 1 h (group 3, N = 10). In 33 patients (82.5%), SAP and diastolic arterial pressure decreased significantly within 5 min after the 10-mg bolus. In group 1, SAP gradually increased after 30-50 min but in groups 2 and 3 SAP remained normal. The triple index (TI) decreased significantly in all groups. Heart rate decreased slightly but significantly in groups 2 and 3. Central venous and left atrial pressures did not change substantially in any of the three groups. Cardiac output increased significantly (0.51 +/- 0.158 L/min); hence, systemic vascular resistance (SVR) decreased significantly (452.1 +/- 50.57 dyn . s . cm-5--group 3). No rebound increase in SAP occurred after terminating the infusions (groups 2 and 3). These findings indicate that 5-HT plays a role in the majority of patients who develop hypertension following CABG. The decrease of SVR without reflex tachycardia is a favorable effect of ketanserin.
Subject(s)
Coronary Artery Bypass , Hypertension/drug therapy , Piperidines/therapeutic use , Serotonin Antagonists/therapeutic use , Female , Heart Rate/drug effects , Hemodynamics/drug effects , Humans , Infusions, Parenteral , Injections, Intravenous , Ketanserin , Male , Middle Aged , Postoperative Complications/drug therapyABSTRACT
The effect of thymopoietin pentapeptide (TP-5) was evaluated in patients with rheumatoid arthritis (RA). Ninety-two patients were divided into 3 groups, namely, placebo, TP-5 intramuscularly (IM) 1 mg, TP-5 intravenously (IV) 50 mg, and were evaluated for 6 measures of disease activity at the beginning of the study and at 3 and 6 months. No difference was observed between the placebo group and the group treated with TP-5 IM 1 mg. However, in the group treated with TP-5 IV 50 mg a statistically significant improvement of all parameters except the ESR was observed.
Subject(s)
Arthritis, Rheumatoid/drug therapy , Hormones/administration & dosage , Peptide Fragments/administration & dosage , Thymopoietins/administration & dosage , Thymus Hormones/administration & dosage , Clinical Trials as Topic , Double-Blind Method , Humans , Injections, Intramuscular , Injections, Intravenous , ThymopentinSubject(s)
Antifungal Agents/administration & dosage , Imidazoles/administration & dosage , Onychomycosis/drug therapy , Piperazines/administration & dosage , Administration, Oral , Adult , Aged , Antifungal Agents/blood , Clinical Trials as Topic , Humans , Imidazoles/blood , Ketoconazole , Long-Term Care , Male , Middle Aged , Onychomycosis/blood , Piperazines/bloodSubject(s)
Antifungal Agents/metabolism , Gastric Acid/metabolism , Imidazoles/metabolism , Piperazines/metabolism , Adult , Antifungal Agents/therapeutic use , Biological Availability , Cimetidine/pharmacology , Cryptococcosis/drug therapy , Female , Humans , Imidazoles/therapeutic use , Ketoconazole , Piperazines/therapeutic useSubject(s)
Imidazoles/therapeutic use , Piperazines/therapeutic use , Aspergillosis/drug therapy , Candidiasis/drug therapy , Candidiasis, Chronic Mucocutaneous/drug therapy , Candidiasis, Oral/drug therapy , Chromoblastomycosis/drug therapy , Coccidioidomycosis/drug therapy , Dermatomycoses/drug therapy , Dose-Response Relationship, Drug , Evaluation Studies as Topic , Histoplasmosis/drug therapy , Humans , Ketoconazole , Mycoses/drug therapy , Onychomycosis/drug therapy , Paracoccidioidomycosis/drug therapy , Pityriasis/drug therapyABSTRACT
An overall analysis was made of 4763 case report forms from 45 anesthesiologists who used etomidate (Hypnomidate) routinely as an induction hypnotic in a total of 4127 surgical cases or compared it to thiopental in a series of controlled studies (325 on etomidate, 311 on thiopental). Premedication was standardized only in the controlled studies, and there were no restrictions on the use of anesthetic agents or techniques. Etomidate proved to be a safe and effective induction hypnotic. Sleep was deep and long enough to allow the normal induction and maintenance procedures. Blood pressure and heart rate remained remarkably stable in the 3 study groups. The incidence of respiratory depression was higher for thiopental; anesthesiologists' acceptance of etomidate was, however, reduced by the occurrence of venous pain during injection and of associated involuntary muscle movements. It is expected that these adverse effects will be largely eliminated by using the recently introduced new formulation of etomidate shortly after fentanyl.
Subject(s)
Etomidate , Imidazoles , Adolescent , Adult , Age Factors , Aged , Blood Pressure/drug effects , Body Weight , Child , Child, Preschool , Etomidate/adverse effects , Etomidate/pharmacology , Fentanyl/pharmacology , Heart Rate/drug effects , Humans , Infant , Middle Aged , Premedication , Thiopental/pharmacology , Time FactorsABSTRACT
The effects of the analgesics sulfentanil (R 30730) and fentanyl, on autonimic stability, cardiovascular stability, respiratory depression and post-operative behaviour were compared in a standardised anaesthetic technique. Twenty-nine patients undergoing neurological arteriographies, were treated with one or more doses of 0.5 mg fentanyl; 22 patients were treated with an initial dose of 0.05 mg of sulfentanil followed by repeat injections of 0.025 mg, when necessary. The analgesic potency of sulfentanil proved to be 12 times that of fentanyl while (in contrast to fentanyl), the duration of the respiratory depression after sulfentanil did not differ significantly from the duration of optimal analgesia. The effects of both drugs on blood pressure and heart rate were minimal; autonomic stability was excellent. No serious side effects were seen in any of the patients. After sulfentanil analgesia the patients were more rapidly awake and lucid, than after fentanyl-analgesia. Further investigations with this new and promising drug seem to be of great interest.